Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 8 Multivariate analysis for patients with dose/fractionation data as a function of radiated site

From: Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis

  Extracranial Radiation (n = 326) Intracranial Radiation (n = 1395)
Hazard Ratio 95% Confidence Interval p-value Hazard Ratio 95% Confidence Interval p-value
Sex Male 1.00 Ref 0.288 1.00 Ref 0.0006
Female 0.85 0.64–1.14 0.80 0.70–0.91
Age 18–59 1.00 Ref 0.104 1.00 Ref 0.042
60–69 1.41 0.98–2.06 1.06 0.91–1.24
70–79 1.47 0.98–2.21 1.25 1.05–1.48
80+ 2.09 0.97–4.10 1.30 0.96–1.71
Comorbidity 0 1.00 Ref 0.481 1.00 Ref 0.009
1 1.18 0.83–1.64 0.99 0.85–1.16
> 2 1.27 0.74–2.04 1.42 1.12–1.77
Histology Adenocarcinoma 1.00 Ref 0.376 1.00 Ref < 0.0001
Non-adenocarcinoma 1.14 0.85–1.53 1.35 1.18–1.55
Race White 1.00 Ref 0.561 1.00 Ref 0.750
Non-white 1.13 0.74–1.66 1.03 0.86–1.22
Insurance Uninsured 1.00 Ref 0.82 1.00 Ref 0.697
Insured 0.91 0.42–2.37 0.89 0.79–1.01
Facility Type Academic 1.00 Ref 0.871 1.00 Ref 0.084
Nonacademic 1.03 0.76–1.40 1.12 0.99–1.27
Systemic Therapy Chemotherapy 1.00 Ref 0.01 1.00 Ref 0.886
Immunotherapy 0.49 0.28–0.82 0.98 0.79–1.21
Biologically Effective Dose ≤60 Gy 1.00 Ref < 0.0001 1.00 Ref 0.538
> 60 Gy 0.34 0.25–0.46 0.96 0.83–1.10